NewAmsterdam Pharma (NASDAQ:NAMSW) Short Interest Down 71.4% in November

NewAmsterdam Pharma (NASDAQ:NAMSW) was the recipient of a significant drop in short interest during the month of November. As of November 30th, there was short interest totalling 1,000 shares, a drop of 71.4% from the November 15th total of 3,500 shares. Based on an average trading volume of 6,800 shares, the short-interest ratio is currently 0.1 days.

NewAmsterdam Pharma Stock Down 0.2 %

NAMSW traded down $0.03 during midday trading on Wednesday, hitting $14.07. 4,037 shares of the company were exchanged, compared to its average volume of 10,144. The firm’s 50 day moving average price is $9.70 and its 200-day moving average price is $8.57. NewAmsterdam Pharma has a 1-year low of $2.38 and a 1-year high of $16.75.

Hedge Funds Weigh In On NewAmsterdam Pharma

A hedge fund recently bought a new stake in NewAmsterdam Pharma stock. TFC Financial Management Inc. purchased a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMSW) in the second quarter, according to its most recent filing with the SEC. The firm purchased 10,000 shares of the company’s stock, valued at approximately $87,000.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.